VRAX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 30, 2026

Report Source: 2026 2nd Quarter Report

Analyst's Ratings for Virax Biolabs Group Ltd (VRAX)

Based on 7 analysts giving stock ratings to Virax Biolabs Group Ltd in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
29
Buy
57
Hold
14
Sell
0
Strong Sell
0
Virax Biolabs Group Ltd

Virax Biolabs Group Ltd. Stock Analysis VRAX

United States Health Care Nano Cap Report:
Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Read More

Virax Biolabs Group Ltd (VRAX) Chart

Key Statistics of Virax Biolabs Group Ltd (VRAX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.14$0.16

Today's Open

$0.14

Volume

1.74M

P/E Ratio (TTM)

-

52 Week Range

$0.10$1.20

Market Cap

2.42M

Avg. Volume

17.84M

Dividend Yield

-

Financial Metrics & Statements of Virax Biolabs Group Ltd (VRAX)

FAQ's for Virax Biolabs Group Ltd (VRAX)

  • According to Musaffa’s Shariah screening methodology, Virax Biolabs Group Ltd (VRAX) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.